126
Participants
Start Date
July 15, 2021
Primary Completion Date
June 23, 2025
Study Completion Date
June 23, 2025
Pembrolizumab
IV infusion
MK-4830
IV infusion
Boserolimab
IV infusion
Lenvatinib
Oral capsule
Etoposide
IV infusion
Cisplatin
IV infusion
Carboplatin
IV infusion
Semmelweis University-Pulmonológiai Klinika ( Site 2802), Budapest
Országos Korányi Pulmonológiai Intézet-XIV. Tüdöbelgyógyászat ( Site 2806), Budapest
Klinik Penzing-2. Lungenabteilung ( Site 2101), Vienna
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2100), Vienna
Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 2801), Törökbálint
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 2800), Szolnok
Zala Megyei Szent Rafael Kórház-Pulmonológia ( Site 2805), Zalaegerszeg
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 2502), Sankt Gallen
Memorial Sloan Kettering Cancer Center ( Site 0115), New York
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0114), Mineola
Seoul National University Bundang Hospital ( Site 1104), Seongnam
UPMC Hillman Cancer Center ( Site 0127), Pittsburgh
The Catholic University Of Korea St. Vincent's Hospital ( Site 1106), Suwon
Ospedale San Raffaele-Oncologia Medica ( Site 2303), Milan
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 2304), Milan
MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore
Virginia Cancer Institute ( Site 0119), Richmond
Chungbuk National University Hospital ( Site 1107), Cheongju-si
St Francis Cancer Center-Research Office ( Site 0117), Greenville
Georgia Cancer Specialists ( Site 0106), Atlanta
Hospital Insular de Gran Canaria ( Site 2402), Las Palmas de Gran Canaria
Baptist Health Lexington-Research ( Site 0108), Lexington
Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland
Parkview Research Center at Parkview Regional Medical Center ( Site 0130), Fort Wayne
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 2300), Siena
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0122), Omaha
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0129), Omaha
University of Colorado Anschutz Medical Campus ( Site 0104), Aurora
Banner MD Anderson Cancer Center ( Site 0102), Gilbert
"GBUZ SPb CRPCstmc(o) ( Site 2705)", Saint Petersburg
N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S, Saint Petersburg
Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 2704), Saint Petersburg
Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 2708), Krasnoyarsk
Rambam Health Care Campus-Oncology ( Site 2600), Haifa
Meir Medical Center ( Site 2601), Kfar Saba
Rabin Medical Center-Oncology ( Site 2604), Petah Tikva
Sheba Medical Center-ONCOLOGY ( Site 2603), Ramat Gan
Shaare Zedek Medical Center ( Site 2602), Jerusalem
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2003), Hamilton
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2005), Kingston
St. Marys Hospital Center ( Site 2000), Montreal
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier, Warsaw
Samodzielny Publiczny Zespó Grulicy i Chorób Puc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemi, Olsztyn
Seoul National University Hospital ( Site 1101), Seoul
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1105), Seoul
Asan Medical Center-Department of Oncology ( Site 1103), Seoul
Samsung Medical Center ( Site 1100), Seoul
Instituto Catalan de Oncologia - Hospital Duran i Reynals ( Site 2403), L'Hospitalet de Llobregat
Hospital Universitari Vall d'Hebron-Oncology ( Site 2401), Barcelona
Merck Sharp & Dohme LLC
INDUSTRY